 |
||
 |
 |
 |
 |
||
Lee D. Arnold PhD
Dr. Arnold has an exceptionally broad research background in synthetic and medicinal chemistry, structure-based drug design, cell biology, biochemistry, drug metabolism, and biophysics. With pharma industry experience from Syntex, Pfizer Central Research, BASF/Abbott Bioresearch, and OSI Pharmaceuticals, he brings a history of over 22 years of industry contributions in molecularly-targeted small-molecule drug discovery in oncology. In his most recent corporate position as Vice President of US Research at OSI Pharmaceuticals, Inc. from 2003 to 2007, Dr. Arnold oversaw discovery research in Cancer Chemistry, Biology, and Leads Discovery.
During his career Dr Arnold has played an integral role in delivering 7 innovative drug candidates into development for Oncology. One of his inventions, Tarcevaif ®, the first potent, selective, reversible EGFR inhibitor demonstrated to improve survival in lung and pancreatic carcinoma patients, has become a marketed blockbuster. Four others, including first-in-class selective inhibitors of IGF1-R and TORC1/TORC2 continue to advance in cancer clinical trials.
Dr. Arnold is currently President & CEO of DiscoverElucidations , aiding academic researchers, fledgling biotechs, and large pharma in discovery and development efforts in a range of therapeutic areas. He is also a visiting professor at the State University of New York at Stony Brook and a member of the Institute of Cell Biology and Drug Discovery. He is recognized in oncology drug discovery through his inventorship on over fifty patent filings, thirty peer-reviewed publications, and numerous presentations, disclosing more than 15 distinct chemotypes of kinase inhibitors.
Professor Adrian L Harris
Professor Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford and directs the Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine. He is Director of the Cancer Research UK Medical Oncology Unit at the Churchill Hospital, a Consultant Medical Oncologist, and a Professorial Fellow of St Hugh's College Oxford. He is Head of the CRUK Oxford Cancer Centre and the Oxford Experimental Cancer Medicine Centre. He is Editor-in-Chief of the British Journal of Cancer.
Professor Harris trained in Medicine and Biochemistry at Liverpool University, did a DPhil at Oxford University then trained at the Royal Marsden Hospital in Medical Oncology. He was appointed Professor of Clinical Oncology at Newcastle-upon-Tyne in 1982. Since 1988 he has been the Professor of Medical Oncology at Oxford University,
His major laboratory interests involve the role of hypoxia in tumour biology and angiogenesis; and new drug development. He is investigating the roles of hypoxia and Notch signalling in angiogenesis, micro RNAs induced by hypoxia and hypoxia induced cell death. He specialises in breast cancer and has previously treated a wide range of tumour types including urological cancers, lung cancer, gynaecological cancers and haematological malignancy. He has published over 800 scientific papers and reviews.
Robert Jackson PhD
Dr Jackson retired in 2007 from the position of Chief Scientific Officer at Cyclacel Ltd. (Dundee and Cambridge, UK, and Berkeley Heights, New Jersey, USA). Previous roles included Head of Research & Development positions at Celltech, Chiroscience Group plc, and Agouron Pharmaceuticals Inc., and positions at Du Pont Pharmaceuticals and Warner-Lambert/Parke-Davis. He has been involved in a senior capacity (either as Project Manager or R&D Director) in taking 25 new drugs to clinical trial, including five which were taken through to marketing approval in one or more countries: pentostatin, trimetrexate, oxantrozole, nelfinavir, and chirocaine.
Consulting positions held by Dr Jackson include: member and chairman of the Experimental Therapeutics Study Section (Division of Research Grants, NIH); member of the Board of Scientific Counsellors for the Developmental Therapeutics Program at NCI; and currently, Chairman of the CR-UK Discovery Committee; Deputy Chair, CRUK Clinical and Translational Research Committee; and member of the Scientific Advisory Board for Cancer Research Technology.
Dr Jackson is the author of more than 100 peer-reviewed publications, 30 reviews and book chapters, and 2 single-author books in the area of anticancer and anti-infective drug discovery and development.
